CRISPR screening in primary human T cells: Extending cell type capabilities
02 Oct 2020
Genetic screens are powerful tools to interrogate cell responses to drug treatment as well as microenvironment perturbations. With the increasing interest in manipulating the immune system to tackle disease and the use of CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 genome editing systems, screening primary cells is both appealing and feasible.
In this webinar, Cristina Ghirelli, immuno-oncology manager at Horizon Discovery, discusses the development of a pipeline to perform pooled CRISPR screening in primary T cells through a combined lentiviral and electroporation approach. With a protocol validated using culture settings previously published in Jurkat T cells (Birsoy et al., 2015), Horizon Discovery treated primary T cells were used to identify new metabolic targets involved in cell proliferation control and survival. Next-generation sequencing data not only confirmed some Jurkat hits, but also revealed new specific T cell targets.
Key learning objectives:
- Human T cell gene editing
- Donor variability in T cells CRISPR screening
- NGS data analysis for genetic screenings
Who should attend:
- Scientists, (any level), with a specific interest in CRISPR screening in primary human cells
- Scientists, (any level), looking for CRISPR technology optimization
- Scientists, (any level,) with a particular interest in T cell target identification
Certificate of attendance
All webinar participants can request a certificate of attendance, and a learning outcomes summary document for continuing education purposes.